The research on lapatinib in autophagy, cell cycle arrest and epithelial to mesenchymal transition via Wnt/ErK/PI3K-AKT signaling pathway in human cutaneous squamous cell carcinoma

Ming Yao, Yuan Yuan Shang, Zhi Wei Zhou, Yin Xue Yang, Yin Sheng Wu, Li Feng Guan, Xin Yu Wang, Shu Feng Zhou, Xi Wei

Research output: Contribution to journalArticlepeer-review

Abstract

Cutaneous squamous cell carcinoma (cSCC) contributes to one of most common types of skin cancer. Epidermal growth factor receptor (EGFR) activation has been investigated to be associated with the development of cSCC. Lapatinib is an inhibitor targeting HER2/neu and EGFR pathway. We found that lapatinib can inhibit proliferation by enhancing apoptosis of human cSCC cell lines. The cSCC cell cycle distribution could be arrested in G2/M phase after lapatinib treatment. In the in vitro experiment, we found that lapatinib interrupted PI3K/AKT/mTOR signaling pathway in human cSCC cells. Furthermore, lapatinib could suppress epithelial to mesenchymal transition (EMT) via Wnt/ErK/PI3K-AKT signaling pathway to represent a promising anticancer drug for cSCC treatment.

Original languageEnglish (US)
Pages (from-to)220-226
Number of pages7
JournalJournal of Cancer
Volume8
Issue number2
DOIs
StatePublished - 2017
Externally publishedYes

Keywords

  • Cutaneous squamous cell carcinoma (cSCC)
  • Epithelial to mesenchymal transition
  • Lapatinib
  • Proliferation

ASJC Scopus subject areas

  • Oncology

Fingerprint

Dive into the research topics of 'The research on lapatinib in autophagy, cell cycle arrest and epithelial to mesenchymal transition via Wnt/ErK/PI3K-AKT signaling pathway in human cutaneous squamous cell carcinoma'. Together they form a unique fingerprint.

Cite this